ABSTRACT
The relevance of the research is determined by the growth of cases of abdominal tuberculosis (AT), which is difficult to diagnose. AIM: Identify clinical features and possibilities of timely AT diagnosis. MATERIALS AND METHODS: Medical reports of 116 AT patients. The results of clinical, microbiological, immunological, radiological, endoscopic and morphological studies were analyzed. THE RESULTS: AT proceeded under the mask of ulcerative colitis and Crohn's disease (26.3%), alcoholic and biliary hepatitis (11.8%), lymphoproliferative and oncological diseases (61.8%), often generalized against the background of HIV-infection. The duration of the diagnostic search for disease verification exceeded 3 months due to incorrect (erroneous) interpretation of intoxication (26.3%) and radiological pattern in the lungs (23.7%), non - application and late application of laparoscopy (39.5%). CONCLUSION: When diagnosing AT, it is necessary to consider the peculiarities of its clinic and to conduct timely laparoscopy.
Subject(s)
Colitis, Ulcerative , Crohn Disease , General Practitioners , HIV Infections , Tuberculosis , Diagnosis, Differential , HumansABSTRACT
For the first time, the synthesis of organosilicon derivatives of dialkyl[1]benzothieno[3,2-b][1]-benzothiophene (BTBT) capable of forming a semiconducting monolayer at the water-air interface is reported. Self-assembled monolayer organic field-effect transistors prepared from these materials using the Langmuir-Blodgett technique showed high hole mobilities and excellent air stability.
ABSTRACT
CHEK2 is classified as a moderate-penetrance gene for hereditary breast cancer (BC). In Russia, CHEK2 mutations hold second position in the list of BC-predisposing gene defects after BRCAl, and include CHEK2 1100deIC, de15395, and IVS2+lG>A gene-inactivating alleles. CHEK2-driven breast carcinomas are generally characterized by poor prognosis and low sensitivity to the conventional therapeutic regimens. CHEK2 testing needs to be incorporated into routine clinical practice owing its overt clinical significance.
Subject(s)
Breast Neoplasms/genetics , Checkpoint Kinase 2/genetics , Genetic Diseases, Inborn/genetics , Mutation , Penetrance , BRCA1 Protein/genetics , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Breast Neoplasms/therapy , Female , Genetic Diseases, Inborn/diagnosis , Genetic Diseases, Inborn/mortality , Genetic Diseases, Inborn/therapy , Humans , Prognosis , Russia/epidemiologyABSTRACT
Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/analysis , Breast Neoplasms/drug therapy , Molecular Targeted Therapy/methods , Neoadjuvant Therapy/methods , Receptor, ErbB-2/analysis , Adult , Aged , Antibodies, Monoclonal, Humanized/administration & dosage , Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Female , Humans , Inflammatory Breast Neoplasms/drug therapy , Lapatinib , Middle Aged , Quinazolines/administration & dosage , Trastuzumab , Treatment OutcomeSubject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Biomarkers, Tumor/analysis , Breast Neoplasms/drug therapy , Neoplasms, Hormone-Dependent/drug therapy , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Aromatase Inhibitors/therapeutic use , Breast Neoplasms/chemistry , Chemotherapy, Adjuvant , Drug Administration Schedule , Female , Humans , Neoplasms, Hormone-Dependent/chemistry , Premenopause , Tamoxifen/therapeutic use , Treatment OutcomeABSTRACT
Nanobiotechnology, defined as an arm of a nano-system is a rapidly developing area of medicine. Nanomaterials ranging from 1 to 1000 nm in size offer unique advantages of interaction with biological systems on the molecular level. Nanobiotechnologies can be used in definition, diagnosis and treatment of cancer thus leading to the new development of a new discipline--nanooncology. The potential of nanoparticles to be used in in-vivo tumor visualization, biomolecular profiling of tumor growth factors and targeted drug delivery is being studied. These methods stemming from nanotechnology may soon find a broad application in oncology.
